id: benzodiazepine_treatment_protocol_to_adverse_event_risk
name: Benzodiazepine Treatment Protocol for AWS â†’ Serious Adverse Effects Risk
from_node:
  node_id: benzodiazepine_treatment_protocol
  node_name: Benzodiazepine Treatment Protocol for AWS
to_node:
  node_id: adverse_event_risk
  node_name: Serious Adverse Effects Risk
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Benzodiazepines as standard treatment for alcohol withdrawal syndrome carry
  inherent risks including respiratory depression, oversedation, and cognitive impairment'
- 'Step 2: These adverse effects may necessitate higher levels of monitoring, extended
  hospitalization, or intensive care transfers'
- 'Step 3: Safety concerns limit treatment accessibility for patients with contraindications
  and increase healthcare system burden through extended resource utilization'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Kristina Karapetyan et al. 2023. "Evaluation of Gabapentin and
    Baclofen Combination for Inpatient Management of Alcohol Withdrawal Syndrome.."
    *Federal practitioner : for the health care professionals of the VA, DoD, and
    PHS*. https://doi.org/10.12788/fp.0362'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.746303'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: patient_comorbidities
  direction: strengthens
  strength: strong
  description: Patients with respiratory conditions, liver disease, or concurrent
    substance use face amplified risks from benzodiazepine treatment
- name: polypharmacy
  direction: strengthens
  strength: moderate
  description: Concurrent medications increase drug-drug interaction risks and adverse
    event probability with benzodiazepines
